Antibiotic Incentives: Pfizer’s Read Touts Exclusivity Voucher

 
• By Sue Sutter

Providing a transferable period of patent-life extension in exchange for US FDA approval of a new antibiotic would incentivize ‘the whole ecosystem’ to find new treatments for emerging diseases, CEO Ian Read says.

Ian Read
• Source: Source: Courtesy of Noel St. John/National Press Club

More from Pricing Debate

More from Market Access